Rifapentine (RPT), sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis.[1] In active tuberculosis it is used together with other antituberculosis medications.[1] In latent tuberculosis it is typically used with isoniazid.[2] It is taken by mouth.[1]

Clinical data
Other names3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin
  • C
Routes of
by mouth
ATC code
Pharmacokinetic data
Bioavailabilityincreases when administered with food
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.057.021
Chemical and physical data
Molar mass877.031 g/mol g·mol−1
3D model (JSmol)
Melting point179 to 180 °C (354 to 356 °F)

Common side effects include low neutrophil counts in the blood, elevated liver enzymes, and white blood cells in the urine.[1] Serious side effects may include liver problems or Clostridium difficile associated diarrhea.[1] It is unclear if use during pregnancy is safe.[1] Rifapentine is in the rifamycin family of medication and works by blocking DNA-dependent RNA polymerase.[1]

Rifapentine was approved for medical use in the United States in 1998.[1] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] In the United States it costs $100–200 per month.[4] In many areas of the world it is not easy to get as of 2015.[5]

Medical uses

A review of alternative regimens for prevention of active tuberculosis in HIV-negative individuals with latent TB found that a weekly, directly observed regimen of rifapentine with isoniazid for three months was as effective as a daily, self -administered regimen of isoniazid for nine months. But the rifapentine-isoniazid regimen had higher rates of treatment completion and lower rates of hepatotoxicity. However, the rate of treatment-limiting adverse events was higher in the rifapentine-isoniazid regimen. [6]


Rifapentine has been assigned a Pregnancy Category C by the FDA. Rifapentine in pregnant women has not been studied, but animal reproduction studies have resulted in fetal harm and were teratogenic. If rifapentine and rifampin are used together in pregnancy, coagulation should be monitored due to a possible increased risk of maternal postpartum hemorrhage and infant bleeding.[7]

Adverse effects

Common side effects are hyperuricemia, pyuria, hematuria, urinary tract infection, proteinuria, neutropenia, anemia, and hypoglycemia.[7]


Rifapentine should be avoided in patients with an allergy to the rifamycin class of drugs.[7] This drug class includes rifampicin and rifabutin. [8]


Rifapentine induces metabolism by CYP3A4, CYP2C8 and CYP2C9 enzymes. It may be necessary to adjust the dosage of drugs metabolized by these enzymes if they are taken with rifapentine. Examples of drugs that may be affected by rifapentine include warfarin, propranolol, digoxin, protease inhibitors and birth control pills.[7]

Chemical structure

The chemical structure of rifapentine is similar to that of rifamycin, with the notable substitution of a methyl group for a cyclopentane (C5H9) group.


Rifapentine was first synthesized in 1965 by the same company that produced rifampicin. The drug was approved by the Food and Drug Administration (FDA) in June 1998.[9] It is made from rifampicin.

See also


  1. "Rifapentine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  2. The selection and use of essential medicines: Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children) (PDF). World Health Organization. 2015. p. 37. ISBN 9789240694941. Archived (PDF) from the original on 20 December 2016. Retrieved 10 December 2016.
  3. "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
  4. Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 53. ISBN 9781284057560.
  5. Nieburg, Phillip; Dubovi, Talia; Angelo, Sahil (2015). Tuberculosis—A Complex Health Threat: A Policy Primer of Global TB Challenges. Rowman & Littlefield. p. 15. ISBN 9781442240957. Archived from the original on 2016-12-20.
  6. Sharma SK; et al. (2013). "Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB". Cochrane Database of Systematic Reviews. 7: CD007545. doi:10.1002/14651858.CD007545.pub2. PMC 6532682. PMID 23828580.
  7. Sanofi-Aventis. (2010) Priftin (rifapentine): Highlights of Prescribing Information. Retrieved from "Archived copy" (PDF). Archived (PDF) from the original on 2017-06-23. Retrieved 2017-09-10.CS1 maint: archived copy as title (link).
  8. CDC. (2013) Core Curriculum on Tuberculosis: What the Clinician Should Know. Retrieved from "Archived copy". Archived from the original on 2017-07-11. Retrieved 2017-09-10.CS1 maint: archived copy as title (link).
  9. FDA (2017). Pediatric Postmarketing Pharmacovigilance Review. FDA.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.